Anti-Human KCNA3 VHH Single Domain Antibody (A019400029) (CAT#: TAB-0070CL-VHH)

Recombinant monoclonal antibody A019400029 is a single domain antibody that specifically binds to human Kv1.3 and can be potentially used in the treatment of autoimmune disease.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Published Data
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 Dose-dependent effect of trivalent A019400029 on human Kv1.3 channels stably expressed in HEK293H.

The correlated concentration-response curve for the inhibition of human Kv1.3 channels.

Inhib

Figure 2 Dose-dependent effect of trivalent A019400029 on human Kv1.3 channels stably expressed in HEK293H.

The current recovery during washout of A019400029

Inhib

Figure 3 Dose-dependent effect of trivalent A019400029 on human Kv1.3 channels stably expressed in HEK293H.

Kv1.3 currents were recorded by automated population patch clamp using a depolarizing voltage protocol with a time interval of 30 s on the IonFlux™ system, A019400029 was sequentially applied to the same cell population by continuous perfusion of each concentration for 120 s. Kv1.3 current traces of A019400029.

Figure 4 Competition of the half-life extended bivalent A019400029 Nanobody construct with I125 margatoxin in absence (closed squares) and presence (closed circles) of HSA

Cyno Kv1.3 was expressed on CHO cells. The counts per minute (cpm) value is plotted against the concentration of the Nanobody. The background (BG) is the control condition where no I125 margatoxin was added and was evaluated in presence (up righted closed triangles) and absence of HSA (down righted closed triangles).

Inhib

Figure 5 Inhibition of IFNγ production in anti-CD3 stimulated human PBMCs by a dilution series of the A019400029 Nanobody construct (closed circles) and ShK toxin (closed squares)

Same Nanobody and toxin do not inhibit IFNγ production in human PBMCs co-stimulated with anti-CD3 and anti-CD28.

Inhib

Figure 6 Inhibition of IFNγ production in anti-CD3 stimulated human PBMCs by a dilution series of the A019400029 Nanobody construct (closed circles) and ShK toxin (closed squares)

The IFNγ concentration (pg/ml) is plotted against the concentration of the Nanobody or toxin. The control condition where cells are not stimulated is indicated by 'no stim'.

Activ

Figure 7 Effect of A019400029 on the voltage-dependence of activation on human Kv1.3 channels stably expressed in CHL cells. Kv1.3 currents were recorded by conventional planar patch clamp.

Superimposed current traces were elicited by a 500 ms depolarizing pulse to +50 mV in 10 mV steps from a holding potential of −80 mV at 30 s intervals in the absence and presence of 10 nM A019400029.

Activ

Figure 8 Effect of A019400029 on the voltage-dependence of activation on human Kv1.3 channels stably expressed in CHL cells. Kv1.3 currents were recorded by conventional planar patch clamp.

The Boltzmann equation was used to fit the curve.

FuncS

Figure 9 Effect of A019400029 on association and washout of Kv1.3 currents on human Kv1.3 channels stably expressed in CHL cells.

Kv1.3 currents were recorded by conventional planar patch clamp using a repeated gating voltage command protocol. Currents were provoked by a test pulse from −80 mV to +40 mV every 15 s. The test pulse duration was either 20 ms.

FuncS

Figure 10 Effect of A019400029 on association and washout of Kv1.3 currents on human Kv1.3 channels stably expressed in CHL cells.

Kv1.3 currents were recorded by conventional planar patch clamp using a repeated gating voltage command protocol. Currents were provoked by a test pulse from −80 mV to +40 mV every 15 s. The test pulse duration was either 200 ms.

FuncS

Figure 11 Effect of A019400029 on association and washout of Kv1.3 currents on human Kv1.3 channels stably expressed in CHL cells

Kv1.3 currents were recorded by conventional planar patch clamp using a repeated gating voltage command protocol. Currents were provoked by a 200 ms test pulse from −80 mV to +40 mV every 15 s. Recordings were done in control conditions (prior to compound addition) and during a 3 to 5 min incubation of 10 nM A019400029, followed by compound washout. During this period of Nanobody incubation, the cells were held at a holding potential of either −80 mV.

FuncS

Figure 12 Effect of A019400029 on association and washout of Kv1.3 currents on human Kv1.3 channels stably expressed in CHL cells

Kv1.3 currents were recorded by conventional planar patch clamp using a repeated gating voltage command protocol. Currents were provoked by a 200 ms test pulse from −80 mV to +40 mV every 15 s. Recordings were done in control conditions (prior to compound addition) and during a 3 to 5 min incubation of 10 nM A019400029, followed by compound washout. During this period of Nanobody incubation, the cells were held at a holding potential of either −40 mV.

FuncS

Figure 13 Effect of A019400029 on recovery from inactivation of Kv1.3 currents on human Kv1.3 channels stably expressed in CHL cells.

The percentage of recovery was calculated and plotted against pulse interval to show the recovery of inactivation.


Specifications

  • Immunogen
  • pVAXl-human Kvl.3 plasmid vector
  • Host Species
  • Llamma
  • Derivation
  • Phage display library
  • Type
  • Single domain antibody
  • Specificity
  • Human
  • Clone
  • A019400029
  • Applications
  • Inhibition, Activation, Functional Assay
  • Related Disease
  • Autoimmune disease

Applications

  • Application Notes
  • The antibody was validated for Inhibition, Activation, Functional Assay. For details, refer to Published Data.

Target

  • Alternative Names
  • KCNA3; potassium channel, voltage gated shaker related subfamily A, member 3; MK3; HGK5; HLK3; PCN3; HPCN3; KV1.3; HUKIII; potassium voltage-gated channel subfamily A member 3; potassium channel 3; type n potassium channel; voltage-gated K(+) channel HuKIII; voltage-gated potassium channel protein Kv1.3; voltage-gated potassium channel subunit Kv1.3; potassium voltage-gated channel, shaker-related subfamily, member 3

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

See other products for "KCNA3"

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart